FOLD (Amicus Therapeutics) Future 3-5Y EPS without NRI Growth Rate : N/A (As of Mar. 04, 2025)

View and export this data going back to 2007. Start your Free Trial

What is Amicus Therapeutics Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Amicus Therapeutics's Future 3-5Y EPS without NRI Growth Rate is N/A.

Competitive Comparison of Amicus Therapeutics's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Amicus Therapeutics's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amicus Therapeutics's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amicus Therapeutics's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Amicus Therapeutics's Future 3-5Y EPS without NRI Growth Rate falls into.

Amicus Therapeutics (NAS:FOLD) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Amicus Therapeutics Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Amicus Therapeutics's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Amicus Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amicus Therapeutics Inc (NAS:FOLD) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

0HF9:UK AM6:Germany

Address

47 Hulfish Street, Princeton, NJ, USA, 08542

Website

https://www.amicusrx.com

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

Executives

Bradley L Campbell	director, officer: President and CEO	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Margaret G Mcglynn	director	C/O MERCK & CO INC, ONE MERCK DRIVE PO BOX 100, WHITEHOUSE STATION NJ 08889-0100
John F Crowley	director, officer: Executive Chairman	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
David Michael Clark	officer: Chief People Officer	1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Ellen Rosenberg	officer: General Counsel & Corp. Secy	C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08560
Samantha Prout	officer: Principal Accounting Officer	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Jeff Castelli	officer: VP, Program Management	1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Harford Simon N.r.	officer: Chief Financial Officer	AVON PRODUCTS, INC., 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Michael Raab	director	1119 ST PAUL STREET, BALTIMORE MD 21202
Daphne Quimi	officer: Chief Financial Officer	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Burke W Whitman	director	13455 NOEL ROAD # 2000, DALLAS TX 75240
Eiry Roberts	director	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEO CA 92130
Hung Do	officer: Sr Vice President Discovery	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Michael Aaron Kelly	director	C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., NEW YORK NY 10016
Jay Barth	officer: Chief Medical Officer	C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512